Stock PAVM PAVMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus PAVmed Inc.

Equities

PAVM

US70387R4039

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.87 USD -0.53% Intraday chart for PAVmed Inc. 0.00% -54.61%
Mar. 27 Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
Mar. 25 PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on PAVmed Inc.

Price target over the last 5 years

History of analyst recommendation changes

9b004e.xbS5_f2TzQsO9wsI9ASqix9FTBtrbqBBrHX9LZa6kg0.oOTtv7PXg0Ffr2FJmVvf3EgTDTYjF9MR_wWrVPXqwmyL-NuQusKdVD2mYA~a6dac7db1403aec3e7acf8ff68c18fa8

Analyst Recommendations on PAVmed Inc.

Cantor Fitzgerald Downgrades PAVmed to Neutral From Overweight, Cuts Price Target to $1.50 From $4 MT
Lake Street Adjusts PAVmed's Price Target to $1.50 From $5, Maintains Buy Rating MT
Lake Street Trims Price Target on PAVmed to $5 From $7, Reiterates Buy Rating MT
Cantor Fitzgerald Adjusts PAVmed's Price Target to $5 from $6, Keeps Overweight Rating MT
PAVMED : Cantor Fitzgerald Starts PAVmed at Overweight With $8 Price Target MT
PAVMED : Ascendiant Capital Starts PAVmed at Buy With $5 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.88 USD
Average target price
15.38 USD
Spread / Average Target
+717.82%
High Price Target
26 USD
Spread / Highest target
+1,282.98%
Low Price Target
4 USD
Spread / Lowest Target
+112.77%

Consensus detail

Consensus revision (last 18 months)

Analysts covering PAVmed Inc.

Cantor Fitzgerald
Lake Street

Ratings for PAVmed Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PAVM Stock
  4. Consensus PAVmed Inc.